Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 6/20 | 0.43 |
| ▸ | DRD1 | P21728 | 3/20 | 0.43 |
| ▸ | DRD5 | P21918 | 3/20 | 0.43 |
| ▸ | HTR1A | P08908 | 10/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.34 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.34 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3674423 | 0.86 | HTR1A (0.36) | DRD2HTR1A | |
| SCHEMBL3678644 | 0.79 | DRD1 (0.39) | DRD2DRD1DRD5HTR1AHRH3 | |
| SCHEMBL3680945 | 0.72 | HTR2A (0.42) | DRD2DRD1DRD5ACHE | |
| SCHEMBL11010302 | 0.69 | DRD1 (0.48) | DRD2DRD1DRD5HTR1A | |
| SCHEMBL3668711 | 0.65 | TH (0.35) | DRD2DRD1HTR1A | |
| SCHEMBL11378015 | 0.63 | SLC6A2 (0.49) | DRD2DRD1HTR1AADRA1DADRA1A | |
| SCHEMBL8315948 | 0.60 | DRD2 (0.46) | DRD2HTR1A | |
| Hydrochloric Acid SCHEMBL10836174 | 0.60 | ADRA1B (0.47) | DRD2HTR1AADRA1AADRA1B | |
| SCHEMBL11372179 | 0.60 | HTR1A (0.42) | DRD2DRD1HTR1AADRA1DADRA1A | |
| SCHEMBL11089335 | 0.59 | DRD2 (0.44) | DRD2DRD1DRD5HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100041690-A1 | Co-Administration of Dopamine-Receptor Binding Compounds | DARPHARMA, INC. | 2010-02-18 | — | — | US | disclosed |
| US-20070254906-A1 | Method of Administration of Dopamine Receptor Agonists | DARPHARMA, INC. (US) | 2007-11-01 | — | — | US | disclosed |
| US-20070155720-A1 | Co-administration of dopamine-receptor binding compounds | DARPHARMA, INC. (US) | 2007-07-05 | — | — | US | disclosed |
| US-20050232870-A1 | Method of treatment of dopamine-related dysfunction | PURDUE RESEARCH FOUNDATION AND UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 2005-10-20 | — | — | US | disclosed |
| US-6916823-B2 | Method of treatment of dopamine-related dysfunction | PURDUE RESEARCH FOUNDATION (US) | 2005-07-12 | — | — | US | disclosed |
| US-6916832-B2 | Chromeno[4,3,2-de]isoquinolines as potent dopamine receptor ligands | UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2005-07-12 | — | — | US | disclosed |
| US-20050080266-A1 | CHROMENO[4,3,2-DE]ISOQUINOLINES AS POTENT DOPAMINE RECEPTOR LIGANDS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-04-14 | — | — | US | disclosed |
| EP-1192161-B1 | CHROMENO[4,3,2-DE]ISOQUINOLINES AS POTENT DOPAMINE RECEPTOR LIGANDS | PURDUE RESEARCH FOUNDATION (US) | 2003-05-21 | — | — | EP | disclosed |
| US-20020132827-A1 | Using full D1 dopamine receptor agonists in an intermittent dosing protocol with a short, but essential, \"off-period.\ | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2002-09-19 | — | — | US | disclosed |
| US-6413977-B1 | D1 AGONISTS; CENTRAL AND PERIPHERAL NERVOUS SYSTEM DYSFUNCTIONS; IMPROVING COGNITION AND MEMORY; PARKINSON'S DISEASE, SCHIZOPHRENIA, ATTENTION-DEFICIT HYPERACTIVITY, SUBSTANCE ABUSE, PHYSIOLOGICAL FUNCTION | PURDUE RESEARCH FOUNDATION | 2002-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041690-A1 | Co-Administration of Dopamine-Receptor Binding Compounds | DRD2, DRD1, DRD3 | DRD2 1/4885DRD1 2/4885DRD5 15/4885 |
| US-20050232870-A1 | Method of treatment of dopamine-related dysfunction | DRD2, DRD1, DRD3 | DRD2 1/4885DRD1 2/4885DRD5 11/4885 |
| US-20070254906-A1 | Method of Administration of Dopamine Receptor Agonists | ADRA1D, DRD2, CHRM3 | DRD2 2/4885DRD1 5/4885DRD5 62/4885 |
| US-20050080266-A1 | CHROMENO[4,3,2-DE]ISOQUINOLINES AS POTENT DOPAMINE RECEPTOR LIGANDS | DRD2, COMT, CHRM3 | DRD2 1/4885DRD1 30/4885DRD5 67/4885 |
| US-20020132827-A1 | Using full D1 dopamine receptor agonists in an intermittent dosing protocol with a short, but essential, \"off-period.\ | DRD2, DRD1, DRD3 | DRD2 1/4885DRD1 2/4885DRD5 7/4885 |
| US-20070155720-A1 | Co-administration of dopamine-receptor binding compounds | DRD2, DRD1, DRD3 | DRD2 1/4885DRD1 2/4885DRD5 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.